| Project/Area Number |
09671141
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Hematology
|
|---|
| Research Institution | Tazuke Kofukai Medical Research Institute |
|---|
Principal Investigator |
YAGITA Masato Tazuke Kofukai Medical Research Institute, Department of II, CHIEF, 医学研究所・第2研究部, 部長 (60220125)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
MIYAKE Masayuki Tazuke Kofukai Medical Research Institute, Department of V, CHIEF, 第5研究部, 部長 (90250076)
|
|---|
| Project Period (FY) |
1997 – 1998
|
| Project Status |
Completed (Fiscal Year 1998)
|
| Budget Amount *help |
¥1,000,000 (Direct Cost: ¥1,000,000)
Fiscal Year 1998: ¥1,000,000 (Direct Cost: ¥1,000,000)
|
|---|
| Keywords | MRP-1 / CD9 / prognosis of AML / poor prognostic factor / 微小残存白血病 |
|---|
| Research Abstract |
We investigated the relationship between MRP-1/CD9 expression and clinical prognosis of patients with acute leukemia(AML and ALL) in a multi-institutional study during these two years (in 1997 and 1998).
The flowcytometric analysis showed that more than half of cases with acute leukemia (25 out of 52 cases) were positive (>50% positive) for MRP/CD9 expression. When the MRP/CD9 expression was examined in FAB-subgroups of acute leukemia, 8 out of 15 cases with AML-M1, 5 out of 8 with M3, 9 out of 12 with M4 and 5, and all 3 cases with ALL (B-cell type) were positive for MRP/CD9 expression. In contrast, all eleven cases with AML-M2 were negative for this antigen expression. With respect to the correlation with the clinical prognosis, 12 out of 17 cases with MRP-1/CD9 positive AML (Ml, 4 or 5) were unsuccessful to induce remission or resulted in relapse in a short period (in less than 6 months). Moreover, these MRP-1/CD9 positive AML cases(M1, M4, and M5)showed shorter survival time (both total and disease-free) in comparison with negative cases. These findings indicated that the MRP-1/CD9 expression was the poor prognostic factor for AML.
|
